Check out our most popular compounded medications! Get Started
Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are compounded with Methocel E4M, a controlled-release polymer. This formulation is designed to gradually release the medication over an extended period, providing sustained therapeutic effects and improved patient compliance. These capsules are used to treat conditions such as Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, and Progressive Supranuclear Palsy.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are a compounded medication specifically designed to treat a range of neurological conditions, including Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, and Progressive Supranuclear Palsy. This unique formulation utilizes Methocel E4M, a controlled-release polymer, to ensure a gradual and sustained release of the active ingredients, Carbidopa and Levodopa, over an extended period of time.
The slow release mechanism of this formulation offers several benefits. It provides a steady therapeutic effect, reduces the frequency of dosing, and improves patient compliance, particularly for those requiring a controlled and prolonged release profile. The combination of Carbidopa and Levodopa in this formulation is designed to minimize the metabolism of Levodopa in the body, thereby enhancing the efficient delivery of the medication to the brain.
As a result, this formulation can effectively alleviate symptoms associated with these neurological conditions, such as tremors, stiffness, and difficulty with movement. It is a testament to the advancements in pharmaceutical compounding and its potential in providing personalized treatment options for patients.
At Bayview Pharmacy, we are committed to offering this innovative formulation to our patients. Our team of compounding pharmacists are well-versed in the intricacies of this medication and are available to answer any questions you may have about Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules and its role in managing your condition. Please do not hesitate to reach out to us for any queries or concerns.
Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are a compounded formulation specifically designed for the treatment of neurological disorders such as Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, and Progressive Supranuclear Palsy. The capsules are formulated with Methocel E4M, a type of controlled-release polymer, which ensures the gradual release of the encapsulated medication over an extended period of time. This slow and steady release offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.
Carbidopa is an inhibitor of aromatic amino acid decarboxylase, an enzyme responsible for the conversion of levodopa to dopamine. Dopamine is a neurotransmitter that is deficient in patients with Parkinson's Disease. By inhibiting this enzyme, Carbidopa reduces the peripheral metabolism of levodopa, allowing more of the drug to reach the brain and exert its therapeutic effects. This formulation is designed to provide a slow and steady release of levodopa, which helps to reduce the occurrence of side effects such as nausea and vomiting.
It is important to note that this formulation should not be used in combination with other dopaminergic medications, as this may increase the risk of adverse effects. Patients should also be monitored for signs of neuroleptic malignant syndrome, a rare but potentially fatal side effect of levodopa. If you have any questions about the use of Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules for the treatment of Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, or Progressive Supranuclear Palsy, please consult with a healthcare professional.
Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules are a compounded formulation of two medications, Carbidopa and Levodopa, used in the treatment of various neurological conditions. These conditions include Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, and Progressive Supranuclear Palsy. The combination of these two medications works synergistically to manage the symptoms of these conditions.
Carbidopa is an inhibitor of the enzyme aromatic amino acid decarboxylase, which is responsible for the conversion of levodopa to dopamine. By inhibiting this enzyme, Carbidopa ensures that more Levodopa is available to be converted into dopamine in the brain. Levodopa, on the other hand, is a precursor of dopamine, a neurotransmitter that is deficient in patients with Parkinson's Disease and other similar conditions.
The unique feature of this formulation is its slow-release mechanism. The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This polymer is designed to release the encapsulated medication or active ingredient gradually over an extended period of time. This slow-release formulation provides a steady release of the medication, allowing for more consistent symptom control. It offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile.
When taken as directed, Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules can help to reduce the symptoms of the aforementioned neurological conditions. The medication works by increasing the amount of dopamine available in the brain, which helps to improve motor control and reduce tremors, stiffness, and other symptoms associated with these conditions.
It is important to note that Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules should not be used to treat any other condition. The dosage and frequency of administration will vary depending on the individual and the condition being treated. It is crucial to take the medication as prescribed and not to change the dosage or frequency without consulting your healthcare provider.
If you have any questions about Carbidopa 50 mg/Levodopa 200 mg Slow Release Capsules or how it works to treat Parkinson's Disease, Restless Leg Syndrome, Dystonia, Multiple System Atrophy, or Progressive Supranuclear Palsy, please consult with your healthcare provider or pharmacist.
This is a compounded formulation of two medications, Carbidopa and Levodopa, encapsulated in a controlled-release polymer called Methocel E4M. This formulation is designed to gradually release the medication over an extended period of time.
Methocel E4M is a type of controlled-release polymer. It is used in this formulation to ensure that the medication is released gradually over a prolonged period, offering sustained therapeutic effects and reducing the frequency of dosing.
Slow-release formulations offer several benefits. They provide sustained therapeutic effects, reduce the frequency of dosing, and improve patient compliance, especially for medications that require a controlled and prolonged release profile.
As this is a slow-release formulation, the frequency of dosing is typically reduced. However, the exact dosing schedule should be determined by your healthcare provider based on your specific medical condition and response to therapy.
Carbidopa is used in combination with Levodopa to treat the symptoms of Parkinson's disease. It works by preventing the breakdown of Levodopa in the body, allowing more Levodopa to reach the brain and reduce the symptoms of Parkinson's disease.
Levodopa is a medication used to treat the symptoms of Parkinson's disease. It works by being converted to dopamine in the brain, helping to control movement and reduce symptoms such as shakiness, stiffness, and difficulty with walking.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Do not double the dose to catch up. Always consult your healthcare provider to ensure the information applies to your personal circumstances.
Side effects may include nausea, vomiting, loss of appetite, and feeling lightheaded. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.
Before starting this medication, tell your doctor or pharmacist of all the drugs you are taking, especially of certain anti-seizure drugs, antipsychotic drugs, and high blood pressure medications. Drug interactions may change how your medications work or increase your risk for serious side effects.
Do not stop taking this medication without consulting your doctor. Some conditions may become worse when this drug is suddenly stopped. Your dose may need to be gradually reduced.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
